Is compounded semaglutide still legal after the FDA shortage ended? FDA’s dated statements

Is compounded semaglutide still legal after the FDA shortage ended?

FDA has not published a single yes or no; its dated records say the semaglutide injection shortage was resolved on February 21, 2025, and the grace periods FDA announced for compounders ended on April 24, 2025 for state-licensed pharmacies (503A) and May 22, 2025 for outsourcing facilities (503B). On April 1, 2026 FDA stated that semaglutide is on neither the 503B bulks list nor its drug shortage list, and on April 30, 2026 it proposed not adding it to the 503B bulks list.

This page lists what FDA has published, with dates. It is not legal advice and does not say whether any company’s product is lawful.

FDA’s statements describe conditions under which compounding can qualify for exemptions in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. For how the two kinds of compounder differ, see 503A pharmacies and 503B outsourcing facilities.

FDA’s statements, by date

FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date. Each statement was re-checked against its source page on Nov 15, 2026.

Current status in FDA data (Nov 15, 2026)

FDA drug shortage list
No semaglutide injection listed as a current shortage
503B bulks list proposal
No final determination published in the Federal Register docket FDA-2018-N-3240 as of this date
FDA warning letters naming compounded semaglutide
117
Telehealth letters naming semaglutide issued after the 503B grace period ended
109
Recall reports naming semaglutide
52

Telehealth letters naming semaglutide since May 22, 2025

False or misleading claims / misbranded55
Unapproved or misbranded drugs sold online54

Common questions

Can telehealth companies still sell compounded semaglutide after the shortage ended?

FDA’s records set conditions rather than a yes or no: compounding under section 503A needs an individual prescription and may not regularly copy an approved drug, and outsourcing facilities may compound from bulk semaglutide only if it is on the 503B bulks list or the shortage list, which FDA said on April 1, 2026 it is not. Since May 22, 2025, FDA has issued 109 warning letters to telehealth companies naming semaglutide, most in the group “False or misleading claims / misbranded” (55).

Is semaglutide on FDA’s drug shortage list?

No semaglutide injection is listed as a current shortage in FDA’s data as of Nov 15, 2026.

What is the 503B bulks list?

It is FDA’s list of bulk drug substances outsourcing facilities may use in compounding because FDA found a clinical need. On April 30, 2026 FDA proposed not to include semaglutide, tirzepatide and liraglutide; the comment period was extended to July 30, 2026.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.